GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CytoSorbents Corp (NAS:CTSO) » Definitions » Valuation Rank

CTSO (CytoSorbents) Valuation Rank


View and export this data going back to 2005. Start your Free Trial

What is CytoSorbents Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

CytoSorbents Valuation Rank Related Terms

Thank you for viewing the detailed overview of CytoSorbents's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

CytoSorbents Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CytoSorbents Corp (NAS:CTSO) » Definitions » Valuation Rank
Comparable Companies
ICCM OWLT ZOMDF XTNT ICAD HYPR RDGL VNRX PTHL APYX ABT BSX SYK MDT XTER:SHL EW SZSE:300760 DXCM XAMS:PHIA ZBH
Traded in Other Exchanges
HQE1:Germany
Address
305 College Road East, Princeton, NJ, USA, 08540
Website
https://www.cytosorbents.com
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
Executives
Edward Raymond Jones director 70 HOGAN LANE, AMBLER PA 19002
Kathleen P. Bloch officer: Chief Financial Officer 3 PERSHING COURT, NORTH BRUNSWICK NJ 08902
Vincent Capponi officer: Chief Operating Officer MEDASORB TECHNOLOGIES, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Phillip P. Chan director, officer: President and CEO 1001 BRIGGS ROAD, SUITE 280, MOUNT LAUREL NJ 08054
Efthymios Deliargyris officer: Chief Medical Officer C/O PLX PHARMA,INC.8285 EL RIO STREET, SUITE 210, HOUSTON TX 77054
Jiny Kim director C/O CYTOSORBENTS CORPORATION, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Alan D. Sobel director 293 EISENHOWER PARKWAY, LIVINGSTON NJ 07039
Michael G. Bator director C/O CYTOSORBENTS CORP., 7 DEER PARK DR., SUITE K, MONMOUTH JUNCTION NJ 08852
Alex D'amico officer: Chief Financial Officer 10 EAST PASSAIC AVENUE, UNIT C-2, NUTLEY NJ 07110
Al Kraus director MEDASORB TECHNOLOGIES, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Eric R. Mortensen officer: Chief Medical Officer C/O CYTOSORBENTS CORPORATION, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Njtc Investment Fund, Lp 10 percent owner 1001 BRIGGS ROAD, SUITE 280, MOUNT LAUREL NJ 08054
Robert Shipley 10 percent owner 9 NOBLE ROAD, NOGALES AZ 85621
Ronald Berger officer: See Remarks 7 DEERPARK DRIVE, STE K, MONMOUTH JUNCTION NJ 08852
Thomas Bocchino officer: Chief Financial Officer C/O CYTOSORBENTS CORP., 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852